Management tracks: Vertex taps Bozic as CMO; plus Nektar, Sangamo, Ascletis, Neurocrine, Neovacs, Dyne, Avidity, Pulmotect, Adaptimmune and 4BIO

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said SVP and Head of Global Clinical Development Carmen Bozic will become EVP, global medicines development and medical affairs. She will take on the additional role of CMO on April 1 when Reshma Kewalramani leaves the position to succeed Jeffrey Leiden as president

Read the full 474 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE